AI-Generated Summary

India's central government has proposed the cancellation of Sresan Pharmaceuticals' license following the deaths of over 20 children linked to their contaminated 'Coldrif' cough syrup, which contained lethal levels of diethylene glycol. The final decision rests with the Tamil Nadu Food and Drug Administration, despite recommendations from the CDSCO for license revocation. This incident underscores critical failures in manufacturing compliance and regulatory oversight.

In a nutshell

This development highlights the paramount importance of stringent quality control, manufacturing compliance, and robust regulatory enforcement in the pharmaceutical industry. For our audience, it serves as a critical case study on the severe consequences of regulatory lapses and the complex interplay between central and state drug authorities.

Source: Lokmat Times